Innovations in Data-Driven Approaches to Improve Sepsis Care for Children in Resource-Constrained Settings

# Community Risk Stratification and Referral to Higher-level Care

Dr. Arjun Chandna

Research Physician, Angkor Hospital for Children, Siem Reap, Cambodia

Wellcome Trust Doctoral Training Fellow, University of Oxford, UK



Infectious Diseases & Microbiology Registrar, University College London Hospitals, UK







@arji barji

## Plan

- Importance of use-cases
- Community assessment of paediatric febrile illness in resource-constrained settings in 2022
- Guiding referral of young children with respiratory infections (the Maela ARI study)
  - Clinical severity scores
  - Biomarkers
- Spot Sepsis trial

# Importance of use-cases

- Differences in case-mix
- Distributions of predictors
- Prevalence of outcomes



• Standardise and contextualise outcomes to understand predictor performance

Study (setting)	Outcome	Prevalence	e Cutoff	PLR (95% CI)	NLR (95% CI)				
OUTCOME: Mortality, organ dys	function or PICU admission								
Lactate									
Scott 2017 (USA)	30d mortality	1.9 %	≥4mM	2.60 (1.16 - 5.83)	0.87 (0.71 - 1.05)				
Mtove 2011 (Tanzania)	In-hospital mortality	5.0 %	> 5mM	5.13 (4.34 - 6.08)	0.49 (0.41 - 0.59)				
Nadjm 2013 (Tanzania)	In-hospital mortality	5.1 %	> 5mM	5.00 (4.21 - 5.93)	0.48 (0.40 - 0.58)				
Scott 2012 (USA)	Organ dysfunction (24h)	5.4 %	≥ 4mM	4.97 (1.90 - 12.98)	0.74 (0.51 - 1.06)	<b>(</b> )			
George 2015 (East Africa)	In-hospital mortality (48h)	9.9 %	> 5mM	2.28 (2.10 - 2.47)	0.34 (0.27 - 0.42)	•	•		
Aramburo 2018 (East Africa)	In-hospital mortality (72h)	10.3 %	≥ 5mM	2.63 (2.47 - 2.79)	0.13 (0.09 - 0.19)	•	•••••••		
						l.	1	//	<u></u>
Chandna et al., BMJ Glob H	lealth, 2021					0	20	40	100
,							Probability of Ou	tcome (%)	

## **Importance of use-cases**

Standardise and contextualise outcomes to understand predictor performance



Use-case	Healthcare context	Example resources	Possible outcomes	BMJ Global Health Anticipating the future: prognostic tools as a complementary strategy to improve care for patients with febrile illnesses in recourse limited settings
Community	<b>CHW / VHW</b> (iCCM)	<ul> <li>Lay person</li> <li>MUAC tapes, thermometers, RR counter</li> <li>Malaria RDTs</li> <li>Antipyretics, ACTs, ORS, multivitamins</li> </ul>	<ol> <li>Persistence of symptoms</li> <li>Worsening of symptoms</li> <li>Referral</li> <li>Hospital admission</li> </ol>	Arjun Chandna , <sup>1,2</sup> Jennifer Osborn, <sup>3</sup> Quique Bassat , <sup>4,5,6,7,8</sup> David Bell , <sup>9</sup> Sakib Burza, <sup>10</sup> Valérie D'Acremont, <sup>11,12</sup> B Leticia Fernandez-Carballo, <sup>3</sup> Kevin C Kain, <sup>13</sup> Mayfong Mayxay, <sup>2,14,15</sup> Matthew Wiens, <sup>16,17,18,19</sup> Sabine Dittrich , <sup>2,3</sup>
referral	<b>PHC / OPD</b> (IMCI or IMAI)	<ul> <li>Nurse, midwife, clinical officer</li> <li>Pulse oximeter, weighing scale, stethoscope</li> <li>RDTs, basic haematology</li> <li>Antibiotics, nebulisers, IV fluids</li> </ul>	<ol> <li>Hospital admission</li> <li>Length of stay</li> <li>Critical care admission</li> <li>Organ dysfunction</li> </ol>	
In-hospital prioritisation	<b>IPD / ICU</b> (WHO Pocket Book)	<ul> <li>Nurse, clinical officer, physician</li> <li>Range of clinical equipment</li> <li>Range of diagnostics</li> <li>Range of therapeutics</li> </ul>	<ol> <li>Critical care admission</li> <li>Critical care length of stay</li> <li>Organ dysfunction</li> <li>Mortality</li> </ol>	COLAB
Post-discharge follow-up	IPD	<ul> <li>Nurse, clinical officer, physician</li> <li>Ability to look at trends during admission</li> <li>Access to community outreach</li> <li>Primary care liaison</li> </ul>	<ol> <li>Readmission</li> <li>Return to baseline</li> <li>Neurocognitive outcomes</li> <li>Mortality</li> </ol>	For Pediatric Sepsis wfpiccs.org/pediatric-sepsis-colab



#### **NMENTAL SCAN**



rg/pediatric-sepsis-colab borealisdata.ca/dataverse/EnviroScan SepsisCoLab

### ASSESSMENT

















Geographic Climatic Security Political Financial Sociocultural

# **Community assessment of paediatric febrile illness in 2022**



Katie Lobner<sup>3</sup>, Gabor Kelen<sup>1</sup> and Lee Wallis<sup>2</sup>

### **Risk scores / prediction models**

			Outcome prevalence	е			
Study (setting)	Model	Outcome	(%)				AUROC (95% CI)
OUTCOME: Mortality, organ s	upport, or PICU admission	1	121				
George 2015 (East Africa)	PEDIA Late death	In-hospital mortality (>48h)	1		<b></b>		0.55 (0.40, 0.69)
Kwizera 2019 (Rwanda)	Model 1	In-hospital mortality	1.5			<b>—</b>	0.79 (0.75, 0.81)
Kwizera 2019 (Rwanda)	Model 2	In-hospital mortality	1.5		+		0.70 (0.60, 0.79)
Kwizera 2019 (Rwanda)	Model 3	In-hospital mortality	1.5		+		0.72 (0.64, 0.91)
Kwizera 2019 (Rwanda)	Model 4	In-hospital mortality	1.5				0.80 (0.78, 0.80)
Kwizera 2019 (Rwanda)	Model 5	In-hospital mortality	1.5		+		0.72 (0.57, 0.80)
van Nassau 2018 (The Netherlands)	SIRS	PICU transfer and/or in-hospital mortality	2.9			-	0.64 (0.53, 0.74)
George 2015 (East Africa)	PEDIA Immediate death	In-hospital mortality (<4h)	3		1000 H	•	0.75 (0.68, 0.83)
van Nassau 2018 (The Netherlands)	qPELOD-2	PICU transfer and/or in-hospital mortality	3.3		+	22.50	0.60 (0.45, 0.76)
van Nassau 2018 (The Netherlands)	qSOFA	PICU transfer and/or in-hospital mortality	3.7		+		0.72 (0.57, 0.88)
George 2015 (East Africa)	PEDIA Early death	In-hospital mortality (4-48h)	4		+-		0.70 (0.63, 0.77)
Conroy 2015 (Uganda)	SICK	In-hospital mortality	4.7			-+	0.85 (0.83, 0.86)
Conroy 2015 (Uganda)	PEDIA Early death	In-hospital mortality	4.7			-+	0.90 (0.88, 0.91)
Conroy 2015 (Uganda)	LODS	In-hospital mortality	4.7			-+	0.90 (0.88, 0.91)
George 2015 (East Africa)	AQUAMAT	In-hospital mortality (48h)	5			•	0.74 (0.65, 0.83)
Lowlaavar 2016 (Uganda)	Model 1	In-hospital mortality	5			<b>—</b>	0.85 (0.80, 0.89)
Lowlaavar 2018 (Uganda)	Model 2	In-hospital mortality	5			<b>—</b>	0.84 (0.79, 0.89)
Lowlaavar 2016 (Uganda)	Model 3	In-hospital mortality	5		-	<b>+</b>	0.82 (0.72, 0.91)
George 2015 (East Africa)	PRISM III	In-hospital mortality (48h)	6				0.71 (0.61, 0.81)
George 2015 (East Africa)	LODS	In-hospital mortality (48h)	7		-	<b></b>	0.77 (0.72, 0.82)
George 2015 (East Africa)	FEAST-PET	In-hospital mortality (48h)	7			<b></b>	0.82 (0.77, 0.87)
George 2015 (East Africa)	FEAST-PETaL	In-hospital mortality (48h)	7			<b>—</b>	0.86 (0.82, 0.90)
van Nassau 2018 (The Netherlands)	qSOFA-lactate	PICU transfer and/or in-hospital mortality	7.9	( <del></del>			0.67 (0.50, 0.84)
George 2015 (East Africa)	Bedside PEWS	In-hospital mortality (48h)	9		<b>—</b>		0.64 (0.56, 0.71)
Walia 2018 (India)	YOS	Mortality	11			٠	0.89
Scott 2020 (USA)	Scott model (Temporal set)	Hypotensive septic shock (24h)	11				0.75 (0.69, 0.81)
Scott 2020 (USA)	Scott model (Geographic set)	Hypotensive septic shock (24h)	14				0.87 (0.73. 1.00)
Walia 2016 (India)	YOS	Mechanical ventilation	17				• 0.97
OUTCOME: Length of stay, du	uration of symptoms						
Elshout 2015 (The Netherlands)	Elshout model	Fever >3d after recruitment	13.1		<b></b>		0.64 (0.58, 0.70)
van Nassau 2018 (The Netherlands)	gPELOD-2	Length of hospital stay >/=7d	22.2	+			0.51 (0.45, 0.57)
van Nassau 2018 (The Netherlands)	gSOFA	Length of hospital stay >/=7d	22.2	( <b>-</b>	•		0.53 (0.46, 0.59)
van Nassau 2018 (The Netherlands)	gSOFA-lactate	Length of hospital stay >/=7d	22.2		<u> </u>		0.56 (0.46, 0.67)
van Nassau 2018 (The Netherlands)	SIRS	Length of hospital stay >/=7d	22.2		-		0.49 (0.44, 0.54)
				1			
				.4	.0	.8	1
					AURO	C	

**BMJ Global Health** Predictors of disease severity in children presenting from the community with febrile illnesses: a systematic review of prognostic studies

Arjun Chandna <sup>(9)</sup>, <sup>1,2</sup> Rainer Tan, <sup>3,4,5</sup> Michael Carter, <sup>6</sup> Ann Van Den Bruel, <sup>7</sup> Jan Verbakel, <sup>7,8</sup> Constantinos Koshiaris, <sup>8</sup> Nahya Salim, <sup>9,10</sup> Yoel Lubell, <sup>2,11</sup> Paul Turner <sup>(9)</sup>, <sup>1,2</sup> Kristina Keitel<sup>5,12</sup>

- Few studies
- Hospitalised children
- Infeasible LMIC primary care
- Lack of external validation



Primary outcome: supplemental oxygen (SpO<sub>2</sub> < 90%)</li>

🔺 Mae La

Mae Ramat

Wang Pha

Mae Sot

Mawker Tai

Myawaddy

China

Romaine et al., Pediatrics, 2020; Beane et al., J Acute Med, 2017; Leclerc et al., Ped Crit Care Med, 2017

	Overall	Supplemental oxygen			
<b>Baseline Characteristics</b>	N = 3.010	No	Yes		
		N = 2,906	N = 104		
Age (months)	8.1 (3.7, 13.7)	8.2 (3.8, 13.8)	7.3 (3.4, 12.7)		
Male sex	<b>53%</b> (1,592 / 3,010 <b>)</b>	53% (1,541 / 2,906)	49% (51 / 104)		
Gestation (weeks)	<b>39.1</b> (38.1, 40.0)	39.2 (38.2, 40.0)	38.4 (37.3, 39.7)		
Birthweight (kg)	2.9 (2.6, 3.2)	2.9 (2.6, 3.2)	2.6 (2.0, 3.0)		
Symptom duration (days)	3.0 (2.0, 5.0)	3.0 (2.0, 5.0)	3.0 (2.0, 5.0)		
Fever	65% (1,958 / 3,005)	65% (1,885 / 2,901)	70% (73 / 104)		
Cough	92% (2,767 / 3,010)	92% (2,667 / 2,906)	96% (100 / 104)		
Respiratory distress*	17% (508 / 3,009)	<b>14%</b> (416 / 2,905)	<b>88%</b> (92 / 104)		
Lung crepitations	<b>39%</b> (1,158/2,941)	38% (1,085 / 2,844)	75% (73 / 97)		
Heart rate (bpm)					
Neonate	140 (132, 150)	<b>140</b> (132, 148)	<b>150</b> (140, 165)		
Infant	138 (128, 144)	<b>136</b> (128, 144)	<b>147</b> (137, 154)		
Child	<b>128</b> (120, 140)	<b>128</b> (120, 140)	<b>140</b> (128, 149)		
Respiratory rate (bpm)					
Neonate	48 (45, 56)	<b>48</b> (44, 54)	<b>65</b> (54, 77)		
Infant	48 (42, 56)	<b>48</b> (42, 56)	<b>58</b> (54, 66)		
Child	45 (38, 52)	<b>44</b> (38, 52)	<b>57</b> (47, 62)		
Axillary temperature (°C)	<b>36.6</b> (36.0, 37.5)	<b>36.6</b> (36.0, 37.4)	<b>36.8</b> (36.2, 37.8)		
Capillary refill time > 2 secs	1.4% (36 / 2,568)	<b>1.1%</b> (27 / 2,476)	<b>9.8%</b> (9 / 92)		
Not alert	13% (372 / 2,973)	<b>11%</b> (306 / 2,875)	<b>67%</b> (66 / 98)		
Weight-for-age z-score (WAZ)	-0.9 (-1.6, -0.2)	<b>-0.9</b> (-1.6, -0.2)	<b>-1.9</b> (-3.4, -0.8)		

Variable part of clinical score(s)

\*Respiratory distress = head bobbing, grunting, nasal flaring, tracheal tug and/or chest indrawing

Median (IQR) reported for continuous variables

### **External validation of the existing scores**



### **Conversion to prediction models**





### Decision curves – referral decisions based on the models vs. LqSOFA score vs. refer all vs. refer none

Treat All

Treat None

LqSOFA model

mSIRS model

qPELOD-2 model



**Threshold probability of 5%** = one correct referral is valued as much as 19 incorrect referrals (1 TP  $\approx$  19 FP)

**Threshold probability of 20%** = one correct referral is valued as much as 4 incorrect referrals (1 TP  $\approx$  4 FP)

Referral threshold	Sensitivity	Specificity	Negative Likelihood Ratio	Positive Likelihood Ratio	Cases referred (%)	Cases managed in community (%)	Ratio of Incorrect to Correct referrals	Ratio of Correct to Incorrect cases managed in community
LqSOFA mo	del							
5%	0.86	0.89	0.16	7.45	423 (14.1%)	2587 (85.9%)	4 to 1	171 to 1
10%	0.74	0.93	0.28	11.15	270 (9.0%)	2740 (91.0%)	3 to 1	100 to 1
20%	0.61	0.97	0.41	17.96	161 (5.3%)	2849 (94.7%)	2 to 1	68 to 1
LqSOFA sc	ore							
≥ 1	0.80	0.86	0.23	5.89	407 (16.1%)	2118 (83.9%)	5 to 1	131 to 1
≥ <b>2</b>	0.23	0.98	0.78	15.49	68 (2.7%)	2457 (97.3%)	3 to 1	39 to 1
≥ 3	0.01	1.00	0.99	15.09	1 (< 0.01%)	2524 (> 99.9%)	0 to 1	31 to 1



Risk-stratification of febrile African children at risk of sepsis using sTREM-1 as basis for a rapid triage test

Aleksandra Leligdowicz<sup>©</sup><sup>1</sup>, Andrea L. Conroy<sup>©</sup><sup>2</sup>, Michael Hawkes<sup>3</sup>, Melissa Richard-Greenblatt<sup>4</sup>, Kathleen Zhong<sup>4</sup>, Robert O. Opoka<sup>5</sup>, Sophie Namasopo<sup>6</sup>, David Bell<sup>®</sup><sup>7</sup>, W. Conrad Liles<sup>8</sup>, Bruno R. da Costa<sup>9</sup>, Peter Jüni<sup>9,11</sup> & Kevin C. Kain<sup>®</sup><sub>0</sub><sup>10,1184</sup>



Prognostic Accuracy of Soluble Triggering Receptor Expressed on Myeloid Cells (sTREM-1)-based Algorithms in Febrile Adults Presenting to Tanzanian Outpatient Clinics Melisea Richard-Greenblatt.<sup>6</sup> Noemie Boillat-Blanco,<sup>7</sup> Kathleen Zhong,<sup>1</sup> Zainab Mbarack,<sup>2</sup> Josephine Samaka,<sup>4</sup> Tarsis Mlaganile,<sup>4</sup> Thekla Kazimoto,<sup>4</sup>

#### **RESEARCH ARTICLE**

#### sTREM-1 predicts mortality in hospitalized patients with infection in a tropical, middleincome country

Shelton W. Wright<sup>1</sup>, Lara Lovelace-Macon<sup>2</sup>, Viriya Hantrakun<sup>3</sup>, Kristina E. Rudd<sup>4</sup>, Prapit Teparrukkul<sup>5</sup>, Susanna Kosamo<sup>2</sup>, W. Conrad Liles<sup>6</sup>, Direk Limmathurotsakul<sup>3,7</sup> and T. Eoin West<sup>2,8\*</sup> <sup>(2)</sup>



#### Table 4 Discrimination of mortality by LASSO-selected biomarkers

Model	AUC	95% CI	p value <sup>a</sup>
IL-8+Ang-2+sTREM-1	0.83	0.79-0.87	Ref
IL-8	0.77	0.73-0.81	0.002
Ang-2	0.77	0.73-0.82	0.0002
sTREM-1	0.81	0.77-0.85	0.07



Check for updates Cytokine

journal homepage: www.elsevier.com/locate/cytokine

Dysregulation of angiopoietin-Tie-2 axis in ugandan children hospitalized with pneumonia

Ran Zhang<sup>a</sup>, Urvi Rai<sup>a</sup>, Nafeesah Bte Mohamed Ibrahim<sup>a</sup>, Yanni Amazouz<sup>a</sup>, Jeremy Soo<sup>a</sup>, Andrea L. Conroy<sup>b</sup>, Sophie Namasopo<sup>c,1</sup>, Robert O. Opoka<sup>d</sup>, Ravi Bhargava<sup>e</sup>, Michael T. Hawkes<sup>f<sub>0</sub>g,h<sub>1</sub>,j<sub>\*</sub></sup>



#### **Pediatric Cardiology**

#### **Endothelial Dysfunction in Childhood Infection**

 Marietta Charakida, MD; Ann E. Donald, AVS; Mari Terese, BSc (Hons), AVS; Sam Leary, PhD; Julian P. Halcox, MB, MA, MRCP; Andy Ness, PhD, MFPH; George Davey Smith, MD, DSc, FFPH; Jean Golding, PhD, DSc, FMedSci; Peter Friberg, MD, PhD; Nigel J. Klein, PhD, FRCPCH; John E. Deanfield, BA, BCh, MB, FRCP; for the ALSPAC (Avon Longitudinal Study of Parents and Children) Study Team



### PEDIATRICS

### Accuracy of a Modified qSOFA Score for Predicting Critical Care Admission in Febrile Children

Sam T. Romaine, BSc, MBChB,<sup>a</sup> Jessica Potter, BSc,<sup>as</sup> Aakash Khanijau, BA, BMBCh,<sup>a</sup> Rachel J. McGalliard, MA, BMBCh,<sup>a</sup> Jemma L. Wright, MBChB,<sup>a</sup> Gerri Sefton, BSc, MSc,<sup>a</sup> Simon Leigh, BSc, MSc,<sup>a</sup> Karl Edwardson, BSc,<sup>d</sup> Philip Johnston, BSc,<sup>d</sup> Anne Kerr, BSc, MBBS, MRCPCH,<sup>a</sup> Luregn J. Schlapbach, MD, PhD,<sup>a</sup> Philip Pallmann, PhD,<sup>a</sup> Enitan D. Carrol, MBChB, MD, FRCPCH<sup>a,a</sup>

### scientific reports

OPEN Age-adjusted quick Sequential Organ Failure Assessment score for predicting mortality and disease severity in children with infection: a systematic review and meta-analysis

Sohyun Eun<sup>1</sup>, Haemin Kim<sup>1</sup>, Ha Yan Kim<sup>2</sup>, Myeongjee Lee<sup>2</sup>, Go Eun Bae<sup>3</sup>, Heoungjin Kim<sup>1</sup>, Chung Mo Koo<sup>1</sup>, Moon Kyu Kim<sup>1</sup> & Seo Hee Yoon<sup>120</sup>

( Check for updates

- LqSOFA = aRR, aHR, CRT, AVPU
- Evaluate predictive performance of biomarkers
  - Generate data to guide prospective research
  - Explore diagnosis vs. prognosis

- Supplemental oxygen (SpO<sub>2</sub> < 90%)
- 49/902 (5.4%) met endpoint





Piomarkar	<b>AUC</b> (95% CI)					
DIOMATKET	Univariate	+ LqSOFA				
LqSOFA	0.82 (0.76-0.88)	—				
Ang-2	0.81 (0.74-0.87)	0.91 (0.88-0.94)				
IL-8	0.72 (0.65-0.79)	0.89 (0.85-0.92)				
sVEGFR-1	0.70 (0.62-0.78)	0.89 (0.86-0.93)				
РСТ	0.69 (0.62-0.77)	0.79 (0.70-0.87)				
IL-1	0.68 (0.59-0.77)	0.80 (0.72-0.88)				
IL-6	0.65 (0.56-0.73)					
sTNFR-1	0.64 (0.55-0.72)					
IL-10	0.61 (0.53-0.70)					
CXCL-10 / IP-10	0.58 (0.49-0.66)					
sTREM-1	0.56 (0.49-0.63)					
CRP	0.56 (0.47-0.65)					
Ang-1	0.53 (0.44-0.62)					
CHI3L1	0.51 (0.42-0.60)					



Referral threshold	Sensitivity	Specificity	Negative Likelihood Ratio	Positive Likelihood Ratio	Cases referred (%)	Cases managed in community (%)	Ratio of Incorrect to Correct referrals	Ratio of Correct to Incorrect cases managed in community		
LqSOFA scor	LqSOFA score									
<b>1%</b> (~ ≥ 0)	1.00	0.00	1.00	1.00	871 (100.0%)	0 (0.0%)	18 to 1	_		
<b>5%</b> (~ ≥ 1)	0.77	0.83	0.28	4.38	176 (20.2%)	695 (80.0%)	4 to 1	62 to 1		
<b>20%</b> (~ ≥ 2)	0.21	0.98	0.81	8.77	26 (3.0%)	845 (97.0%)	2 to 1	22 to 1		
<b>40%</b> (~ ≥ 3)	0.02	1.00	0.98	1.00	1 (0.1%)	870 (99.9%)	0 to 1	18 to 1		
LqSOFA + An	g-2									
1%	1.00	0.36	0.00	1.57	574 (65.9%)	297 (34.1%)	11 to 1	Inf to 1		
5%	0.85	0.81	0.18	4.38	197 (22.6%)	674 (77.4%)	4 to 1	95 to 1		
20%	0.45	0.96	0.58	11.51	54 (6.2%)	817 (93.8%)	2 to 1	30 to 1		
40%	0.23	0.99	0.77	21.43	19 (2.2%)	852 (97.8%)	1 to 1	23 to 1		

# Language of prediction

Figure 1. Schematic representation of diagnostic and prognostic prediction modeling studies.



Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement Gary S. Collins, PhD; Johannes B. Reitsma, MD, PhD; Douglas G. Altman, DSc; and Karel G.M. Moons, PhD

**Annals of Internal Medicine** 

Outcome A		Outcome 1		Outcome 2		Outcome 3	
Biomarker	<b>AUC</b> (95% CI)	Biomarker	<b>AUC</b> (95% CI)	Biomarker	<b>AUC</b> (95% CI)	Biomarker	<b>AUC</b> (95%
LqSOFA	0.82 (0.76-0.88)	LqSOFA	0.85 (0.78-0.91)	Ang-2	0.80 (0.70-0.90)	IL-8	0.75 (0.68-0
Ang-2	0.81 (0.74-0.87)	Ang-2	0.74 (0.65-0.84)	IL-8	0.75 (0.64-0.85)	Ang-2	0.72 (0.64-
IL-8	0.72 (0.65-0.79)	sVEGFR-1	0.71 (0.62-0.81)	LqSOFA	0.75 (0.64-0.85)	IL-1	0.71 (0.62-(
sVEGFR-1	0.70 (0.62-0.78)	IL-1	0.71 (0.61-0.81)	РСТ	0.68 (0.56-0.80)	sVEGFR-1	0.67 (0.58-0
РСТ	0.69 (0.62-0.77)	IL-8	0.70 (0.62-0.77)	IL-1	0.66 (0.53-0.79)	РСТ	0.67 (0.58-
IL-1	0.68 (0.59-0.77)	РСТ	0.69 (0.59-0.78)	sVEGFR-1	0.63 (0.51-0.75)	LqSOFA	0.65 (0.57-)

→ PROGNOSTIC

**DIAGNOSTIC** -

### Outcomes

A = Supplemental oxygen during acute illness (853 controls; 49 cases)

- **1** = SpO<sub>2</sub> < 90% at presentation (735 controls; 32 cases)
- 2 = Supplemental oxygen during acute illness, excluding those with SpO<sub>2</sub> < 90% at presentation (848 controls; 23 cases)
- **3** = Supplemental oxygen within next 28 days, excluding those with SpO<sub>2</sub> < 90% at presentation (826 controls; 39 cases)

# **Spot Sepsis**

**Study sites BANGLADESH** – Cox Bazar **CAMBODIA** – Siem Reap **INDONESIA** – Yogyakarta **LAOS** – Salavan, Savannakhet **VIET NAM** – Dong Nai, Hanoi



### **Funders**





Chandna et al., BMJ Open, 2021



<sup>3,336</sup> participants recruited to date

## Take-aways

- **Reliability and validity** of current tools to guide referral from primary to secondary care is **poor**
- Standardisation of (non-mortality) outcomes and contextualisation (of all) outcomes could help data sharing and comparisons across studies
- LqSOFA looks like a promising and practical paediatric version of qSOFA
- Biomarkers should be assessed by the value they add to clinical scores



## **Useful documents**

• TRIPOD guidelines

https://www.equator-network.org/reporting-guidelines/tripod-statement/

- Collection of materials on best practices for prognostic research https://www.prognosisresearch.com/
- Environmental scan to assess level of care

https://borealisdata.ca/dataverse/EnviroScan\_SepsisCoLab

# Thank you to...

- **Supervisors:** Paul Turner, Yoel Lubell, Rafael Perera, Claudia Turner, Nick Day
- Mentors: Sakib Burza, Liz Ashley
- **Colleagues:** Melissa Richard-Greenblatt, Rainer Tan, James Watson, Sabine Dittrich, Lazaro Mwandigha, Yazid Abdad, Constantinos Koshiaris, George Varghese, Nick White
- Team COMRU
- You for listening :)

arjun@tropmedres.ac





